{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "TNDM",
  "name": "Tandem Diabetes Care, Inc.",
  "url": "https://frontierpicks.com/dossiers/TNDM/",
  "json_url": "https://frontierpicks.com/dossiers/TNDM.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "graded_conviction": "LOW",
  "archetype": {
    "code": "a4",
    "n": 4
  },
  "current_thesis": "Beaten-down insulin-pump turnaround; the whole re-rate hinges on the tubeless Mobi (\"Toby\") 510(k) — planned for a Q2 filing but still unconfirmed after the quarter closed 2026-06-30 — plus margins scaling toward a ~60% Q4 exit. Shares bounced off the floor to ~$17 but sell-side stays neutral (Mizuho cut to $20). The 2026-08-06 Q2 print is the next binary.",
  "invalidation_trigger": "A weekly close below $14 forfeits the July recovery base and re-opens the downtrend toward the $9.98 52-week floor. Secondary: the tubeless Mobi 510(k) still unconfirmed at the 2026-08-06 Q2 print, a FY2026 sales guide cut below $1.065B, or diabetes-AID leadership staying with Insulet's Omnipod.",
  "catalyst_date": null,
  "outcome": "PLAYED_OUT",
  "outcome_date": "2026-08-07",
  "invalidation_fired": false,
  "themes": [
    "medtech-diagnostics"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "2026-07-01: launched t:slim X2 Control-IQ+ integration with Abbott FreeStyle Libre 3 Plus in UK, Switzerland, Sweden, Finland, Italy; more EU markets guided later 2026.",
    "Capital structure: $602.6M convertible senior notes against $456.0M cash and equivalents at 2026-06-30 — a standing refinancing and dilution consideration.",
    "GAAP and adjusted results diverge materially: Q2 2026 net loss $21.2M vs positive adjusted EBITDA $6.4M; FY2026 stock-based comp guided at ~$65M.",
    "The Mobi tubeless 510(k) has no publicly scheduled FDA decision date; 510(k) timelines are not pre-announced the way PDUFA dates are.",
    "International is roughly a third of guided FY2026 sales ($335-340M of $1.065-1.085B), carrying FX and country-level reimbursement exposure.",
    "Competitive set is entrenched: Insulet Omnipod 5 in patch pumps, Beta Bionics (Dexcom-paired, Mint ~2027), Medtronic MiniMed patch planned."
  ],
  "body_markdown": "## Current Thesis\nThe leg an investor is buying has changed shape since late July. Through 2026-07-25 this was a cheap, unloved pump maker whose entire re-rate rested on an unconfirmed FDA filing. The 2026-08-06 Q2 print removed that ambiguity: Tandem stated it submitted a 510(k) for Tandem Mobi tubeless capability during the second quarter, reported 57% GAAP gross margin (up 460bps from 52% in Q2 2025), turned adjusted EBITDA positive at $6.4M (3% of sales), and reaffirmed FY2026 sales of $1.065–1.085B. Simply Wall St's 2026-08-09 write-up put the post-print move at +14.8%. Price went from $17.12 on 2026-07-25 to a $22.72 reference close on 2026-08-14, a 77.2% three-month return with RSI(14) at 78.3. What is being bought now is a margin-and-mix pivot — tubed to tubeless on one hardware platform, DME to pharmacy on the supply channel — priced increasingly on delivery rather than on the discount. The near-term problem is that the next hard event is an FDA decision with no published date.\n\n## Bull Case\n- Q2 2026 (reported 2026-08-06): worldwide sales $254.6M, +6% YoY; U.S. $179.3M (+5%), international $75.3M (+7%). Net loss narrowed to $21.2M / $(0.31) per share from $(0.78) in Q2 2025.\n- Margin is the actual story: GAAP gross margin 57% in Q2 2026 vs 52% in Q2 2025, against an FY2026 guide of 56–57% and a management target of roughly 60% exiting Q4. Adjusted EBITDA of $6.4M is a positive print, not a promise.\n- Volume: 22,000+ U.S. pump shipments plus ~11,000 international in Q2 2026, described as up more than 10% both YoY and sequentially — a shipment reacceleration off the 2025 reset year.\n- The gating item cleared its first hurdle. The Mobi tubeless 510(k) was submitted in Q2 2026, converting an \"if they file\" risk into a review-clock risk. The design converts existing Mobi hardware into a tubeless AID system by changing supplies, which lets installed base convert without new pump capex.\n- Channel shift with a stated arithmetic: at a March 2026 investor discussion management framed pharmacy at under 5% of customers / ~7% of sales in Q4 2025 moving to roughly 10% of customers / ~15% of sales in 2026, with contracts across three major PBMs covering ~80% of lives and a ~$350/month net-price assumption on ongoing supplies.\n- International AID expansion is live: the 2026-07-01 launch of t:slim X2 Control-IQ+ with Abbott FreeStyle Libre 3 Plus in the UK, Switzerland, Sweden, Finland and Italy, with further European markets guided for later 2026.\n\n## Bear Case\n- Revenue is not the growth story the tape is now paying for. Q2 sales of $254.560M missed the $254.978M consensus (2026-08-06), and the FY2026 guide of $1.065–1.085B was affirmed, not raised, against a $1.074B estimate.\n- Price has run past the marginal buyer's stated value. On 2026-08-07 Citigroup maintained Neutral and raised its target to $21 — below the 2026-08-14 close of $22.72. RBC maintained Outperform the same day but cut its target to $26. Mizuho's Neutral $20 (2026-07-15) sits further below.\n- Capital structure: $456.0M cash and equivalents against $602.6M of convertible senior notes at 2026-06-30. A strong equity move improves conversion economics for holders and keeps refinancing on the table.\n- The clearance has no date. A 510(k) submitted \"during Q2\" carries no publicly scheduled decision, so the single item the thesis rests on cannot be calendared — and a rally that front-runs it has no event to settle against inside 30 days.\n- Competitive position is still second-mover in tubeless: Insulet's Omnipod 5 holds the patch category, Beta Bionics is Dexcom-paired with a follow-on around 2027, and Medtronic has a MiniMed patch planned. Tandem's tubeless product will launch into an installed competitor base.\n- GAAP profitability remains negative; the $6.4M adjusted EBITDA sits against a $21.2M net loss and ~$65M of guided FY2026 stock-based compensation.\n\n## Setup & Price Structure\nThe narrative is **accelerating**, dated to the 2026-08-06 print and the sessions that followed. The evidence for the label is the change in participation, not the direction alone: a name that traded at $17.12 on 2026-07-25 after a $15.3–$15.5 early-July range closed at $22.72 on 2026-08-14, and the sell-side that had been cutting into weakness (Mizuho $24→$20 on 2026-07-15) started marking up (Citi $17→$21 on 2026-08-07) inside one week of the print.\n\nCrowding and positioning observables, stated as observables: RSI(14) reads 78.3 as of 2026-08-14, above the conventional 70 threshold; the three-month return is 77.2%; the close sits 19.6% under the $28.26 52-week high, so the move has retraced a large share of the prior drawdown without reaching the old high; and spot is above the most recently *raised* neutral-rated target ($21, Citi). No dated company event falls inside the next 30 days, which means the next several weeks of price action have no scheduled resolution attached to them. The recent filings feed shows no insider transactions to characterise either way.\n\nStructurally, the post-print gap zone above the July shelf near $17 is the reference the move is built on. Reclaiming and holding above the $22–23 area keeps the pivot leg intact; unwinding back through $18 would put price inside the pre-print July range and return the name to the basing question it was in three weeks ago.\n\n## Catalyst Calendar (next 30 days)\n- **No confirmed company-specific event dated on or before 2026-09-15.** The Canaccord Genuity Growth Conference appearance on 2026-08-11 has passed; the Q2 call was 2026-08-06.\n- **H2 2026 (no date published)** — FDA decision on the Tandem Mobi tubeless 510(k) submitted during Q2 2026. This can land inside or outside the 30-day window; 510(k) decisions are not pre-scheduled publicly.\n- **2026-09-28 to 2026-10-02 (just outside the window)** — EASD 62nd Annual Meeting, Milan. Sector AID data venue where Insulet, Dexcom, Medtronic and Beta Bionics readouts set the competitive frame.\n- **~2026-11-04 (est.)** — Q3 2026 print. First quarter that tests the roughly 60% Q4 exit-margin path and the pharmacy mix step-up toward ~15% of sales.\n\n## What Would Change Our Mind\nThe structure that would break first is the post-print shelf. The re-rate from $17.12 (2026-07-25) to $22.72 (2026-08-14) was created in a handful of sessions around the 2026-08-06 report; giving that range back would mean the market re-priced the 510(k) submission and the 57% gross margin as insufficient. A weekly close below $18 marks that, and returns the name to the July basing question rather than a pivot leg.\n\nThree non-price conditions would do the same work. First, the Mobi tubeless clearance going unresolved through the ~2026-11-04 Q3 print with no updated timeline from management — a review clock that stretches turns the only near-term product event into a 2027 story. Second, a gross margin below 57% in Q3 or any trim to the 56–57% FY guide, which is the whole basis on which the multiple has expanded. Third, a capital raise or convertible refinancing announced into strength, given $602.6M of converts against $456.0M of cash at 2026-06-30. On the upside case for the label itself: mainstream retail-sentiment coverage clustering with no new fundamental datapoint would move this from accelerating toward saturated, and that shift matters more than any single downgrade.\n\n## Correlation Notes\n- Direct read-across to Insulet (PODD) as the tubeless incumbent: a Tandem tubeless clearance is a share-shift headline for Omnipod, and Insulet quarterly new-patient-start commentary is the cleanest external check on whether the Mobi conversion is taking or not.\n- CGM partners set the platform's reach: Dexcom (DXCM) G7 and Abbott (ABT) FreeStyle Libre 3 Plus compatibility both shipped in 2026, so sensor-side supply or reimbursement news transmits into Tandem's attach rate.\n- Medtronic (MDT) diabetes segment disclosures and Beta Bionics' Mint timeline (~2027) are the other two competitive inputs on the same category.\n- As an unprofitable, converts-financed small-cap medtech, the name carries higher rate and risk-appetite beta than large-cap medtech; index-level small-cap drawdowns tend to hit it harder than the $1.065–1.085B revenue base alone would suggest.\n- International sales of $335–340M guided for FY2026 create FX and European reimbursement sensitivity that large-cap peers dilute across broader portfolios.",
  "first_seen": "2026-06-17",
  "last_analyzed": "2026-08-16T12:24:06+00:00",
  "last_synthesized": "2026-08-16",
  "last_update_source": "watchlist_research",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}